[Click eStock] "ST Pharm, Growth Accelerates with Expansion of Commercialized Products"

Yuanta Securities analyzed on the 24th that ST Pharm's sales are increasing as the number of commercialized products expands, accelerating its growth trend.

Researcher Ha Hyun-soo of Yuanta Securities stated in a report on the same day, "Cumulative sales of Leqvio reached $531 million by the third quarter, a 130% increase compared to the same period last year," adding, "Annual sales this year are expected to reach about $800 million, and Novartis anticipates Leqvio's peak sales to exceed $4 billion."

Leqvio is currently undergoing clinical trials for cardiovascular risk reduction (CVRR) and low-density lipoprotein cholesterol (LDLC) prevention therapies, with clinical data expected to be released in 2026-2027.

Researcher Ha said, "ST Pharm's commercialized products are expected to expand from two to four by the end of this year," and added, "Rytelo (Imetelstat), which the company is presumed to supply as a raw material, received FDA approval in the U.S. last June, and Tryngolza (Olezarsen) obtained FDA approval on the 20th."

He explained, "Rytelo was approved as a treatment for myelodysplastic syndrome (MDS) and is currently undergoing additional indication trials for myelofibrosis (MF) and acute myeloid leukemia (AML)," and "Tryngolza is also conducting clinical trials for severe hypertriglyceridemia treatment, with expected increased demand due to expanded indications."

ST Pharm has secured multiple late-stage development products in its CDMO (Contract Development and Manufacturing Organization) business. Four oligonucleotide-based therapeutics and one small molecule product are expected to receive approval in 2025, among which a vascular edema treatment presumed to be Donidarlosen has an FDA approval decision (PDUFA) date scheduled for August 21, 2025.

He added, "A small molecule new drug for mitochondrial depletion syndrome (MDS) treatment is also expected to be approved in 2025," and analyzed, "Clinical results for Pelacarsen, presumed to be a treatment for atherosclerosis, will be released in 2025. Pelacarsen is a drug that inhibits LP(a), similar to LDL, and it is likely to become a new treatment option for patients at high risk of cardiovascular disease by controlling LP(a) levels that existing statin drugs cannot effectively lower."